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Advanced Parkinson's disease (PD) is frequently associ-
ated with dementia. The pathogenesis of this dementia is
complex, related to deficiency of several biogenic amines
and cortical Lewy body deposition, as well as co-existent
age related brain changes, both of the Alzheimer's type
and vascular. However, degeneration of the cholinergic
neurons in the nucleus basalis of Meynert may have an
important contribution to the cognitive decline. The
dementia of PD has a grave effect on the quality of life of
the patients and their caregivers, as well as negative effect
on their survival. The treatment of dementia associated
with PD therefore must encompass several agents.
Cholinesterase inhibitors, such as rivastigmine, produced
gratifying results. Future studies should define the exact
role of this agent in the treatment of the dementia of PD.
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